The paper is the result of research conducted by collaborators at the Brander Cancer Research Institute and Department of Pathology at New York Medical College and Alfacell. The study demonstrated that silencing the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene (an abundant and ubiquitously expressed housekeeping gene) in human lung adenocarcinoma A549 cells by siRNA was effectively prevented by ONCONASE. While transfection of cells with GAPDH siRNA reduced expression of this protein by nearly 70 percent, the expression was restored in the cells exposed to ONCONASE for 48 or 72 hours. The data thus provide evidence that one of the targets of ONCONASE (ranpirnase) is siRNA... Alfacell's Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
October
(25)
- Vision-Sciences : Advanced, Video-Based Bronchosco...
- Varian Medical Systems : Clinicians in Netherlands...
- Quark : Publication of Study on Use of siRNA again...
- Aerovance : Aerovant Inhalation Powder is Well To...
- Aires Pharmaceuticals : Key Technology License Agr...
- Novartis and Nektar Therapeutics Pulmonary Business
- Ranbaxy & GSK : IND APPLICATION TO DCGI FOR RESPIR...
- Bayer Schering Pharma : Progress in Clinical Progr...
- APT Pharmaceuticals : Phase III Trial of Inhaled...
- NeoGenomics Laboratories Extends Its Cancer Testin...
- BioView : Interim Results of Early Detection Lung ...
- Novartis : Early data show potential for imatinib ...
- Alfacell's ONCONASE(R) Targets siRNA : Paper in Ce...
- Neotropix : Expansion of On-going Clinical Trial f...
- Health Hero Network : Recertification from Nationa...
- Teva Pharmaceutical : Proair® HFA, the Market Lead...
- Gemin X : Key U.S. Patent Issued for Obatoclax
- Kuros Biosurgery and Aeris Therapeutics : Exclusiv...
- REGENERX : RGN-457 for Cystic Fibrosis
- Gilead Complete Response Letter from U.S. Food and...
- MD Biosciences : Preclinical Disease Models at the...
- Medical Acoustics : Results on Efficacy of Medical...
- Arriva Pharmaceuticals : Protein Production Patent
- Dynavax Technologies : Milestone from AstraZeneca
- Advanced Life Sciences : NDA Submission for Cethr...
-
▼
October
(25)
Oct 10, 2008
Alfacell's ONCONASE(R) Targets siRNA : Paper in Cell Cycle
Oct. 9, 2008- Alfacell Corporation (Nasdaq: ACEL ) announced that a paper published in Cell Cycle (2008; Vol. 7, Issue 20) reports that ONCONASE (ranpirnase) targets small interfering RNA (siRNA), likely within the RNA-induced silencing complex (RISC) of the RNA interference (RNAi) mechanism.